A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy

Chao, Xu;Guo, Lili;Zhang, Zhuoli;Zhu, Jingjing;Cui, Yali;et.al.
(2012) PLoS One — Vol. 7, n° 10, p. e40388 (2012)

Files

2012PLoSOne710e40388Chao.pdf
  • Open Access
  • Adobe PDF
  • 401.2 KB
Download

Details

Authors
  • Chao, XuCollege of Life Sciences, Northwest University, Xi'an
    Author
  • Guo, LiliNational Engineering Research Center for Miniaturized Detection Systems
    Author
  • Zhang, ZhuoliNorthwest University, Chicago, Illinois
    Author
  • Zhu, Jingjingorcid-logoKULeuven
    Author
  • Cui, YaliCollege of Life Sciences, Northwest University, Xi'an
    Author
Show more
Abstract
BACKGROUND: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. METHODS: First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). RESULTS: The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p<0.05), following treatment for 33 days. The life span of tumor-bearing mice treated with DOX-PGMNPs-M, DOX-PGMNPs, and DOX were 74.8±9.95, 66.1±13.5, and 31.3±3.31 days, respectively (each p<0.05). CONCLUSION: This simple and adaptive nanoparticle design may accommodate chemotherapy for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers in the near future.
Affiliations
  • KULLaboratory of Molecular Oncology

Citations

  • APA
  • Chicago
  • FWB

Chao, X., Guo, L., Zhang, Z., Zhu, J., Vermorken, A. J., Van de Ven, W. J., Chao, C., & Cui, Y. (2012). A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy. PLoS One, 7(10), e40388. https://doi.org/10.1371/journal.pone.0040388 (Original work published 2012)